TY - JOUR
T1 - Cardiovascular and Metabolic Risk Factors
T2 - How Can We Improve Outcomes in the High-Risk Patient?
AU - Grundy, Scott M
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/9
Y1 - 2007/9
N2 - Risk assessment algorithms, such as that used in the third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) for treating low-density lipoprotein cholesterol, can be used to classify patients' risk for cardiovascular and metabolic problems and to determine the appropriate level of therapeutic intervention. Patients at highest risk should receive the most intensive therapy. The presence of the metabolic syndrome, a clustering of atherogenic risk factors including dyslipidemia, elevated blood pressure, elevated blood glucose, and other problems, confers additional risk for diabetes mellitus and atherosclerotic cardiovascular disease at every level of risk. Pharmacotherapy with lipid-lowering, antiplatelet, antihypertensive, or insulin-sensitizing agents to modify specific risk factors is indicated in patients at higher risk, but lifestyle change (e.g., smoking cessation, weight reduction, increased physical activity, and "heart-healthy" dietary modifications) and blood pressure control can be used across all categories of risk.
AB - Risk assessment algorithms, such as that used in the third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) for treating low-density lipoprotein cholesterol, can be used to classify patients' risk for cardiovascular and metabolic problems and to determine the appropriate level of therapeutic intervention. Patients at highest risk should receive the most intensive therapy. The presence of the metabolic syndrome, a clustering of atherogenic risk factors including dyslipidemia, elevated blood pressure, elevated blood glucose, and other problems, confers additional risk for diabetes mellitus and atherosclerotic cardiovascular disease at every level of risk. Pharmacotherapy with lipid-lowering, antiplatelet, antihypertensive, or insulin-sensitizing agents to modify specific risk factors is indicated in patients at higher risk, but lifestyle change (e.g., smoking cessation, weight reduction, increased physical activity, and "heart-healthy" dietary modifications) and blood pressure control can be used across all categories of risk.
KW - Atherosclerotic cardiovascular disease
KW - Framingham risk score
KW - Lipid-lowering therapy
KW - Metabolic syndrome
KW - Primary prevention
KW - Secondary prevention
UR - http://www.scopus.com/inward/record.url?scp=34548016755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548016755&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2007.06.005
DO - 10.1016/j.amjmed.2007.06.005
M3 - Article
C2 - 17720359
AN - SCOPUS:34548016755
SN - 0002-9343
VL - 120
SP - S3-S8
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 9 SUPPL. 1
ER -